California Neurology Society (CNS) Advocacy

The California Neurology Society’s Advocacy Day on April 13 brought our community together in Sacramento with a shared purpose—to ensure the voice of neurology is heard where it matters most. It was energizing to see neurologists, trainees, and advocates speak directly with legislators about what we witness every day: the challenges our patients face, the strain on our workforce, and the realities of delivering care across California.

Equally meaningful were the connections—colleagues coming together across settings and career stages, grounded in a shared commitment to our patients and to one another.

A week later, that collective effort translated into action. Scott Wiener presented SCR 124 on the Senate floor, and it passed unanimously.

“For the California Neurology Society, which sponsored this resolution, this was a significant milestone. SCR 124 recognizes transportation access as a critical determinant of employment and independence for adults with epilepsy—a population that faces disproportionately high unemployment due to driving restrictions and limited public transit.”

—Jeff Klingman, President

California Neurology Society

This is what advocacy looks like—personal, direct, and impactful.

Thank you to everyone who showed up, spoke up, and made this possible.

— Selim Yilmaz, Legislative Advocate

California Neurology Society

To express your interest in participating in future advocacy days or to get involved with the CNS Legislative Committee, please contact us directly at LEDGE@caneurologysociety.org.

The California Neurology Society is supporting a statewide prospective registry to advance understanding of Multiple Sclerosis (MS) and related autoimmune neurological diseases. Led by Principal Investigator Dr. Johanna Rosenthal, this collaborative effort brings together neurologists from Arrowhead Regional Medical Center, Riverside Community Hospital, and across California.

This registry collects de‑identified laboratory and clinical data—including immunoglobulin subclasses, lymphocyte populations, and flow cytometry results—to evaluate how modern Disease Modifying Therapies (DMTs) affect the immune system.

Participating neurologists submit data from consenting adult patients, with testing performed at standardized intervals before and after treatment.

By freezing and analyzing data quarterly, the registry aims to provide clinicians with meaningful insights into treatment response, support evidence‑based use of high‑cost therapies, and create a long‑term resource for research. The project includes an initial one‑year cohort of 100 patients, with potential for expansion based on findings.